Wegovy weight-loss drugmaker sees revenues skyrocket

The manufacturer of weight-loss stabs Wegovy and also Ozempic, Danish pharmaceutical huge Novo Nordisk, has actually reported a sharp surge in earnings on the back of surging demand for the medications.

Internet revenues were 39. 2bn kroner (₤ 4. 5bn) for the period from January to June, rising 43% from 27. 5bn kroner a year previously.

The company'' s manager said it was offering"extra people than ever before".

Need has been so strong the firm is coming to grips with supply pressures.

Wegovy - an obesity treatment that is taken as soon as a week - tricks individuals right into assuming they'' re currently full, so they wind up eating less and slimming down.

Famous personalities such as Elon Musk are amongst the reported individuals of the medication, which has actually mesmerized Hollywood and also the general public much more commonly given that it was approved by regulatory authorities in the United States in 2021.

Media records have described Wegovy and also Ozempic - a diabetic issues therapy with comparable results - as "miracle" drugs that will stimulate a "revolution" in weight-loss.

On Wednesday, a brand-new test revealed Wegovy has actually been verified to additionally decrease the danger of a stroke or cardiac arrest.

The company hailed it a "landmark trial", stating it would certainly change the means weight problems is concerned and also treated.

The firm additionally stated it was raising its yearly revenues and also sales forecasts.

"The development is driven by enhancing demand for our GLP-1-based diabetes mellitus and weight problems treatments, as well as we are offering much more clients than in the past," stated manager Lars Fruergaard Jorgensen.

Wegovy was authorized for NHS usage previously this year after study suggested individuals could lose more than 10% of their body weight.

In trials, customers usually put weight back on after stopping therapy.